UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 244

Sortiert nach

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab

Annals of oncology, 2004-01, Vol.15 (1), p.129-133

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809

Annals of oncology, 2011-06, Vol.22 (6), p.1382-1391

2011

Link zum Volltext

Verfügbarkeit prüfen

Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(−) EBV(−) HHV8(+) patient

European journal of haematology, 2013-11, Vol.91 (5), p.467-469

2013

Link zum Volltext

Verfügbarkeit prüfen

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Journal of cellular and molecular medicine, 2023-07, Vol.27 (14), p.1928-1946

2023

Link zum Volltext

Verfügbarkeit prüfen

Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non‐Hodgkin's lymphoma

British journal of haematology, 2003-05, Vol.121 (3), p.439-447

2003

Link zum Volltext

Verfügbarkeit prüfen

Position paper on the therapeutic use of rituximab in CD20‐positive diffuse large B‐cell non‐Hodgkin's lymphoma

British journal of haematology, 2003-04, Vol.121 (1), p.44-48

2003

Link zum Volltext

Verfügbarkeit prüfen

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

British journal of haematology, 2008-11, Vol.143 (3), p.395-403

2008

Link zum Volltext

Verfügbarkeit prüfen

Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet

JAAD Case Reports, 2024-06, Vol.48, p.18-22

2024

Link zum Volltext

Verfügbarkeit prüfen

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

Cancer, 2010-11, Vol.116 (21), p.5001-5011

2010

Link zum Volltext

Verfügbarkeit prüfen

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group

European journal of haematology, 2008-03, Vol.80 (3), p.227-235

2008

Link zum Volltext

Verfügbarkeit prüfen

Burkitt‐like lymphoma with 11q aberration

Clinical case reports, 2019-09, Vol.7 (9), p.1823-1824

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

EJHaem, 2023-02, Vol.4 (1), p.108-114

2023

Link zum Volltext

Verfügbarkeit prüfen

Childhood aggressive B‐cell non‐Hodgkin lymphoma in low–middle‐income countries

British journal of haematology, 2022-02, Vol.196 (4), p.849-863

2022

Link zum Volltext

Verfügbarkeit prüfen

Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse

Haematologica (Roma), 2011-07, Vol.96 (7), p.1002-1007

2011

Link zum Volltext

Verfügbarkeit prüfen

Recurrent mantle cell lymphoma in the uterine cervix: a case report

Journal of medical case reports, 2020-09, Vol.14 (1), p.138-138, Article 138

2020

Link zum Volltext

Verfügbarkeit prüfen

Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma

European journal of haematology, 2006-09, Vol.77 (3), p.217-225

2006

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma

Cancer, 2002-08, Vol.95 (3), p.576-580

2002

Link zum Volltext

Verfügbarkeit prüfen

Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non‐Hodgkin lymphoma

British journal of haematology, 2010-03, Vol.148 (5), p.808-810

2010

Link zum Volltext

Verfügbarkeit prüfen

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas

European journal of haematology, 2007-02, Vol.78 (2), p.93-101

2007

Link zum Volltext

Verfügbarkeit prüfen

Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma

European journal of haematology, 2007-08, Vol.79 (2), p.150-154

2007

Link zum Volltext

Verfügbarkeit prüfen

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series

Hematological oncology, 2011-03, Vol.29 (1), p.10-16

2011

Link zum Volltext

Verfügbarkeit prüfen

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S54-S56

2023

Link zum Volltext

Verfügbarkeit prüfen

combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma

Annals of hematology, 2009-05, Vol.88 (5), p.425-432

2009

Link zum Volltext

Verfügbarkeit prüfen

CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study

European journal of haematology, 2000-09, Vol.65 (3), p.188-194

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 244

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(223)

Publikationsform

Artikel
(244)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(211)
Life Sciences & Biomedicine
(210)
Humans
(199)
Male
(145)
Female
(139)
Oncology
(137)
Middle Aged
(126)
Hematology
(119)
Adult
(115)
Aged
(106)
Lymphoma, Non-Hodgkin - Drug Therapy
(106)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(94)
Biological And Medical Sciences
(78)
Medical Sciences
(78)
Treatment Outcome
(76)
Prognosis
(65)
Adolescent
(62)
Cyclophosphamide - Administration & Dosage
(60)
Chemotherapy
(57)
Lymphoma, Non-Hodgkin - Pathology
(57)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809

Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(−) EBV(−) HHV8(+) patient

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non‐Hodgkin's lymphoma

Position paper on the therapeutic use of rituximab in CD20‐positive diffuse large B‐cell non‐Hodgkin's lymphoma

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy

Burkitt‐like lymphoma with 11q aberration

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

Childhood aggressive B‐cell non‐Hodgkin lymphoma in low–middle‐income countries

Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse

Recurrent mantle cell lymphoma in the uterine cervix: a case report

Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma

Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma

Favourable outcome of pneumonia due to novel influenza A/H1N1 2009 virus in a splenectomised adult patient undergoing therapy for non‐Hodgkin lymphoma

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas

Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma

CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study

Aktive Filter

Suchergebnisse filtern